My WordPress Blog
Source: www.lupin.com
Lupin Limited and AbbVie Inc. are pleased to announce that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program. This will provide AbbVie with exclusive global rights to develop and commercialize Lupin’s MALT1 inhibitors. AbbVie will pay Lupin an upfront payment of $30 million USD for an exclusive license to the program. Upon successful completion of regulatory, development and commercial milestones, Lupin is eligible to receive total milestone payments of up to $947 million USD. Additionally, Lupin will be entitled to receive a double-digit royalty on the sales of the product and will retain commercial rights to the program in India.
